Online citations, reference lists, and bibliographies.
← Back to Search

Platinum And Pemetrexed Combination In Advanced Solid Tumors

G. Finocchiaro, P. Zucali, A. Santoro
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Pemetrexed is a third generation multi-target agent able to inhibit at least three crucial enzymes involved in the folate pathway. Pemetrexed is indicated in combination with cisplatin as first line treatment of malignant pleural mesothelioma (MPM) and in mono-chemotherapy as second line treatment of advanced non-small-cell lung cancer (NSCLC). In 2008, the combination of pemetrexed plus cisplatin has gained approval in Europe and in USA for first line therapy limited to non squamous NSCLC patients. More recently, the outcome of a large phase III trial, aimed at evaluating pemetrexed as maintenance therapy, confirmed the efficacy of the drug in non squamous NSCLC patients. Recent data suggest tumour histotype and TS expression levels as the most promising predictors of pemetrexed sensitivity in NSCLC. The aim of this paper is to review literature data about platinum and pemetrexed combination in advanced solid tumors, especially NSCLC and MPM.
This paper references
10.1016/S1359-6349(09)71840-3
9127 The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin
Paolo Andrea Zucali (2009)
et­ al.­ Pemetrexed­ in­ the­ treatment­ of­ advanced­non-squamous­lung­cancer.­Lung Cancer.­2009:141–7
A Rossi (2009)
10.1158/1078-0432.CCR-07-5143
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Y. Ohe (2008)
10.3816/CLC.2009.s.006
Updated clinical information on multitargeted antifolates in lung cancer.
G. Scagliotti (2009)
Phase ­ II ­ study ­ of ­ peme - trexed plus carboplatin in malignant pleural mesothelioma
B Castagneto
Update ­ of ­ phase ­ II ­ trial ­ of ­ peme - trexed plus carboplatin in patients with advanced non - small - cell lung can
S Koshy (2004)
10.1016/S0093-7754(02)70050-X
Pemetrexed in bladder, head and neck, and cervical cancers.
L. Paz-Ares (2002)
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
C. Niyikiza (2002)
10.1007/s10637-007-9060-9
In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
Axel-Rainer Hanauske (2007)
10.1002/cncr.21480
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
R. Zinner (2005)
10.1016/S0065-2571(97)00017-4
Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
C. Shih (1998)
10.1016/S0093-7754(02)70216-9
Pemetrexed in the treatment of selected solid tumors.
A. Adjei (2002)
10.1158/1078-0432.CCR-09-1641
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung
V. Monica (2009)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2007.15.0375
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
G. Scagliotti (2008)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1016/S0093-7754(02)70046-8
Pemetrexed in pancreatic cancer.
H. Kindler (2002)
10.1023/A:1008336931378
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.
C. Manegold (2000)
10.1093/ANNONC/MDG406
Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.
E. Bajetta (2003)
et­ al.­ Front-line­ treatment­ of­ advanced­ non-small-cell­ lung­ cancer­ with­ MTA­ (LY23154,­ Pemetrexed­ disodium,­ALIMTA)­and­cisplatin:­A­multicenter­phase­II­trial.­Ann Oncol
C Manegold (2000)
10.1158/1535-7163.MCT-06-0343
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
S. Chattopadhyay (2007)
10.1200/jco.2009.27.15_suppl.7521
Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer.
G. Scagliotti (2009)
Randomized ­ phase ­ II ­ and ­ pharmaco - genetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non - small - cell lung cancer
SA Burgers (2009)
10.1093/annonc/mdm592
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
M. Cullen (2008)
10.1200/JCO.2008.20.8181
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
J. Patel (2009)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/J.CLINTHERA.2005.09.010
Pemetrexed: a multitargeted antifolate.
K. D. Rollins (2005)
10.1200/JCO.1999.17.10.3009
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1016/S0140-6736(09)61497-5
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
T. Ciuleanu (2009)
10.1097/JTO.0b013e318031cd62
Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial
C. Gridelli (2007)
Sörenson­S,­ et­ al.­A­ randomized­ phase­ III­ trial­ comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
Cullen­MH (2008)
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
G. Scagliotti (2005)
10.1634/THEONCOLOGIST.12-1-20
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.
M. Hayat (2007)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1093/ANNONC/MDF115
Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
S. Clarke (2002)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
J. Vermorken (1984)
Alimta ­ as ­ second - line ­ treatment ­ of ­ non - small - cell ­ lung ­ cancer : ­ A ­ phase ­ II ­ study
K Mattson (2003)
10.1200/JCO.2008.20.9114
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
B. H. Grønberg (2009)
10.1200/JCO.2004.08.163
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
N. Hanna (2004)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.1124/mol.107.042382
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
E. Giovannetti (2008)
10.1016/S0006-2952(03)00287-9
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
J. Sigmond (2003)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1158/1078-0432.CCR-08-0128
Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer
N. Dickgreber (2009)
10.1016/j.lungcan.2009.06.006
Pemetrexed in the treatment of advanced non-squamous lung cancer.
A. Rossi (2009)
Clinical ­ and ­ pharmacokinetic ­ phase ­ I ­ study ­ of ­ multitargeted ­ antifolate ­ ( LY 231514 ) ­ in ­ combination ­ with cisplatin
R Thodtmann (1999)
et­ al.­ Baseline­ thymidylate­ synthetase­ expression according to histological subtypes of non small cell lung cancer
G Scagliotti­ (2009)
Jung­Y,­Kim­TY,­Ham­HS,­ Jong­HS,­ et­ al.­Cytotoxic­ effects of pemetrexed in gastric cancer cells
JH Kim­ (2005)
10.1158/1078-0432.CCR-06-2393
Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
C. Takimoto (2007)



Semantic Scholar Logo Some data provided by SemanticScholar